The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is rec...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/88 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is recommended weekly injection of 4 mg/m2 in 1, 8, 15 days of a 28-day cycle of therapy, as its effectiveness is comparable to the effectiveness of the standard 5-day regime. |
|---|---|
| ISSN: | 1994-4098 1999-8627 |